低分子肝素在老年结直肠癌患者围手术期的应用效果被引量：3

下载PDF

导出

摘要目的探讨老年结直肠癌患者围手术期应用低分子肝素的临床疗效和对免疫功能的影响。方法选取阜阳市第五人民医院普外科2017年4月至2019年5月收治的88例行手术治疗的老年结直肠癌患者,按照随机表法分为应用试验组(46例)与对照组(42例),试验组患者采用低分子肝素治疗。对比两组患者总失血量、术前、术后第1天、3天及5天的D-2聚体、血浆凝血酶原时间(PT)、纤维蛋白原(Fib)值、CD4、CD8、CD4/CD8值的差异。结果两组患者总失血量的差异无统计学意义(t=1.933,P=0.057)。两组患者D-2聚体(F组间/时间/交互=149.96/860.37/116.41)、PT(F组间/时间/交互=818.51/552.94/106.17)、Fib值(F组间/时间/交互=108.51/1097.03/129.49)、CD4(F组间/时间/交互=84.27/233.55/8.35)、CD8(F组间/时间/交互=59.86/10.50/5.56)、CD4/CD8值(F组间/时间/交互=36.52/46.07/37.40)在不同的时间点组内及组间比较,差异有统计学意义(P<0.05)。结论老年患者围手术期应用低分子肝素可以改善患者凝血功能和免疫功能,有利于患者术后的快速康复。

作者高治华冯辉余辉汪强孙震震

机构地区安徽省阜阳市第五人民医院普外科

出处《安徽医学》 2020年第2期160-163,共4页 Anhui Medical Journal

关键词低分子肝素结直肠肿瘤围手术期

分类号 R735.34 [医药卫生—肿瘤]

引文网络
相关文献

参考文献6

1王建宏,房居高,赵丽云,吕誉芳,饶远生,刘海鹰,闫晓娟.低分子肝素在伴有心血管病抗凝抗血小板治疗头颈部肿瘤患者围手术期的应用[J].心肺血管病杂志,2018,37(7):666-669. 被引量：9
2吴银花,赖华,周晓.低分子肝素在高龄宫颈癌患者围术期的应用价值分析[J].重庆医学,2014,43(30):4080-4082. 被引量：3
3关家辉,夏国志.减孔腹腔镜直肠前切除术对老年中高位直肠癌患者术后应激的影响[J].安徽医学,2018,39(10):1271-1273. 被引量：12
4Hua-Xia Cai,Xu-Qi Li,Shu-Feng Wang.Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors[J].World Journal of Gastroenterology,2018,24(44):5046-5056. 被引量：19
5赵伟,曲虹,丁美精,胡小辉.达比加群酯与低分子肝素预防髋关节置换术后下肢深静脉血栓的作用比较[J].安徽医学,2016,37(8):979-981. 被引量：19
6谢波,钱军,李靖,贾建光,李志祥,张晨嵩.腹腔镜辅助Ivor Lewis术对老年食管癌患者围术期免疫应激及肠道屏障功能的影响[J].中华老年医学杂志,2019,38(3):296-299. 被引量：18

二级参考文献33

1Walenga JM,Lyman GH. Evolution of heparin anticoagu- lants to ultra-low-molecular weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer[J]. Crit Rev Oncol Hematol, 2013, 88(1) :1-18.
2Lee AY, Peterson EA. Treatment of cancer-associated thrombosis[J]. Blood,2013,122(14) :2310-2317.
3Lavau-Denes S, Lacroix P,Maubon A, et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study [J]. Cancer Chemother Pharmacol, 2 013,7 2 (1) : 6 5-7 3.
4Hull RD, Townshend G. Long-term treatment of deep- vein thrombosis with low molecular weight heparin: an update of the evidence[J]. Thromb Haemost, 2013,110 (1):14-22.
5Heller S, Krause M. Low molecular weight heparin de- creases thrombosis risk in patients receiving chemothera- py for cancer[J]. Strahlenther Onkol, 2018,189 (6) : 514- 515.
6Eley KA, Parker RJ, Watt-Smith SR. Low molecular weight heparin in patients undergoing free tissue trans- fer following head and neck ablative surgery: review of efficacy and associated complications[J]. Br J Oral Max- illofac Surg, 2013,51 (7) :610-614.
7Schulman Sam,Kearon Clive,Kakkar Ajay K,Schellong Sebastian,Eriksson Henry,Baanstra David,Kvamme Anne Mathilde,Friedman Jeffrey,Mismetti Patrick,Goldhaber Samuel Z.Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. The New England Quarterly . 2013
8JI Weitz,J Hirsh,MM Samama,American College of Chest Physicians.New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest . 2008
9Samama Charles Marc,Vray Muriel,Barré Jeanne,Fiessinger Jean-No?l,Rosencher Nadia,Lecompte Thomas,Potron Gérard,Basile Joseph,Hull Russell,Desmichels Denise.Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Archives of Internal Medicine . 2002
10葛明华,谭卓,何剑锋,刘爱华,王可敬.侧颅底受侵或侧颅底相关头颈部恶性肿瘤的手术治疗[J].中国肿瘤,2008,17(5):407-410. 被引量：7